News 17 abr 2024 Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug develop...
News 04 abr 2024 Galderma completes largest IPO on a global level in Q1 Galderma has banked nearly 2.3 billion Swiss francs following its listing on the SIX Swiss Exchange. The pharma firm was therefore responsible fo...
News 13 mar 2024 PSI developing new cancer therapy Researchers from the Paul Scherrer Institute (PSI) have developed a radiopharmaceutical to combat metastatic neuroendocrine tumors. After having ...
Aktuell 04 abr 2024 Galderma realisiert weltweit grössten Börsengang Die Kotierung an der Schweizer Börse hat Galderma knapp 2,3 Milliarden Franken eingebracht. Damit stellt das Pharmaunternehmen im ersten Quartal ...
Aktuell 26 mar 2024 Zürcher Forschende machen Krebstherapie wieder wirksam Forschende der Universität Zürich und des Universitätsspitals Zürich haben herausgefunden, wie mutierte Blutkrebszellen wieder auf eine Immunther...
Actualités 17 abr 2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
News 19 dez 2023 Top Stories from Western Switzerland (October-December 2023) From achieving top rankings in global innovation to making significant advancements in healthcare and technology, discover Western Switzerland's ...
News 04 dez 2023 Siegfried, a Swiss leader taking innovations to industrial scale for the pharmaceutical industry From a small operation in Aargau to a global CDMO powerhouse, Siegfried's journey reflects strategic growth, innovation, and a deep commitment to...
News 03 nov 2023 EPFL and Novochizol to collaborate on designing more efficient immunotherapies A groundbreaking collaboration between EPFL's Laboratory of Biomaterials for Immunoengineering and Novochizol aims to revolutionize cancer treatm...
News 27 out 2023 UZH researchers develop method for transport of large genes Researchers at the University of Zurich (UZH) have developed a new method for transporting large genes, enabling them to be transferred efficient...
News 20 out 2023 Xlife Sciences becomes main shareholder in 4D Lifetec Xlife Sciences, a listed accelerator and investor in innovative healthcare solutions, has made an investment totalling 23.3 million Swiss francs ...
Actualités 14 fev 2024 L’Université de Fribourg découvre un traitement pour combattre la neuroinflammation liée à l’âge Des scientifiques de l’Université de Fribourg ont découvert un mécanisme révolutionnaire qui pourrait atténuer de manière significative la neuroi...
News 10 out 2023 HES-SO Valais-Wallis and Debiopharm partner up to battle cancer HES-SO Valais-Wallis and Debiopharm have entered a partnership to advance targeted cancer therapy research with novel antibody conjugates.
Aktuell 27 out 2023 UZH-Forschende entwickeln Methode zum Transport grosser Gene Forschende der Universität Zürich (UZH) haben eine neue Methode zum Transport grosser Gene entwickelt. Sie werden effizient und ohne nennenswerte...
Aktuell 10 nov 2023 Forschende heilen Wunden mit Laktobazillen Forschende aus der Schweiz und den USA haben gemeinsam einen Verband entwickelt, der mithilfe von Probiotika Krankheitskeime in chronischen Wunde...
Événements S-GE Facteurs de succès clés pour faire des affaires au Japon 23 abr 2024 10:15–12:10 Zürich Suíça
News 02 jun 2023 Sandoz decides on Basel for headquarters Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected to take place in th...
Actualités 29 jan 2024 L’innovateur en bioproduction Stämm ouvre son centre européen de R&D à Monthey Stämm, une entreprise leader en matière d’innovation dans les technologies de bioprocédés, a annoncé l’ouverture de son nouveau centre de R&D au ...